I wanted to share an analysis I've conducted on Sanofi over the past five years using both comparable methods and a 2-Stage DCF approach. According to my findings, the market value appears to be at least 22% undervalued in comparison with its fair value. Moreover, considering the post-COVID effects on pharmaceutical companies, I believe Sanofi presents a...
Chart is self explanatory. Disclaimer: This is for demonstration and educational purpose only. This is not buying or selling recommendations. I am not SEBI registered. Please consult your financial advisor before taking any trade.
The algorithm is showing a very profitable pattern in SANOFI. First, if the price breaks up we have a clear rally until the top of the channel with a tight stop loss slightly below the break point. On the other hand, if the market is moving down, we should see a break to the downside of the channel, then an easy break of the support and the blue line would be...
#ASTERDM NSE: ASTERDM CMP: 225 TP: 300 SL: 200 TF: <6m RR > ~3 times Return > 33% THYROCARE CNXPHARMA LUPIN SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER BPLPHARMA MARKSANS BIOCON GRANULES IPCALAB LAURUSLABS NATCOPHARM GLAND ALKEM ZYDUSLIFE APOLLOHOSP FORTIS AARTIDRUGS ZYDUSWELL MAXHEALTH BAJAJHCARE Factors: BULLISH WEDGE...
#LUPIN NSE: LUPIN CMP: 756 TP: 910 SL: 700 TF: <6m RR > 3 times Return > 20% THYROCARE CNXPHARMA LUPIN NSE:CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER BPLPHARMA MARKSANS BIOCON GRANULES IPCALAB LAURUSLABS NATCOPHARM GLAND ALKEM ZYDUSLIFE APOLLOHOSP FORTIS AARTIDRUGS Factors: BULLISH WEDGE BREAKOUT Trend Following Rising...
#AUROPHARMA NSE: AUROPHARMA CMP: 437 TP: 535 SL: 400 TF: <6m RR > 3.5 times Return > 22% THYROCARE CNXPHARMA LUPIN NSE:CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising Prices. Flag pattern breakout. Pennant Pattern Breakout with Bullish Candle. Retest...
Sanofi - 30d expiry - We look to Buy a break of 88.01 (stop at 84.48) Previous resistance level of 88 broken. Our short term bias remains positive. Previous resistance, now becomes support at 88. 50 1day EMA is at 86.97. Support is located at 88 and should stem dips to this area. Daily signals are mildly bullish. Our profit targets will be 96.72 and 97.72...
#GLENMARK NSE: GLENMARK CMP: 440 TP: 515 SL: 400 TF: <6m RR > 2 times Return > 17% THYROCARE CNXPHARMA LUPIN NSE:CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER BPLPHARMA MARKSANS BIOCON GRANULES IPCALAB LAURUSLABS NATCOPHARM GLAND ALKEM ZYDUSLIFE Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising...
#CIPLA NSE: CIPLA CMP: 1128 TP: 1250 SL: 1080 TF: <6m RR > 2.5 times Return > 11% THYROCARE CNXPHARMA LUPIN NSE: CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising Prices. Flag pattern breakout. Pennant Pattern Breakout with Bullish Candle. Retest...
Sanofi India has a breakout on DAILY TIMEFRAME. The target will be found 6700 to 7700 Can be bought for long term If it closes below 5300 A stop-loss of 5300 can be maintained
Previously SANOFI was consolidating in weekly chart. Now there is a breakout on upper side. There is 1:14 Risk Reward Long Term Trade Opportunity. Pros: 1. Very High RR Ratio 1:14 2. Expected Waiting Period is around 8-16 Months 3. Target it 50% + 4. Very High Probability as its fundamentally good stock Cons: 1. Gave bad results in recent Quarterly Results We...
This was after 90% Up from 4500 in Jun'19 Plan ahead => could consider to Buy above 6500 - and/ or Rejections near 5000 PB 6x PE 11x ROCE 34% DivYld 8%
Sanofi - 30d expiry - We look to Buy a break of 88.41 (stop at 84.78) Previous resistance level of 83 broken. Short term bias has turned positive. 88.34 has been pivotal. A break of the recent high at 88.34 should result in a further move higher. Prices have reacted from 81.93. Overnight losses have been limited. Our outlook is bullish. Our profit...
Sanofi - Intraday - We look to Buy a break of 83.71 (stop at 79.98) We are trading at oversold extremes. Bullish divergence can be seen on the daily (the chart makes a lower low while the oscillator makes a higher low), often a signal of exhausted bearish momentum, or at least a correction higher. 83.58 has been pivotal. A break of 83.60 is needed to confirm...
1. rsi going up 2. macd about to cross its lines 3. price getting consolidated 4. correction waves are done 5. volume increasing i have no reason why sanofi will fall. one can take trade during this time, and do swing trade TARGET- above 7800. one can even go long term, as this is the most bottom part of Sanofi, and you will getting benefitted later. BUY AND HOLD.
when the waves get completed one could make profits within a short duration. Sanofi is a great company with a good fundamentals, due to FII selling heavily and earnings not reaching the estimate, it has corrected a lot. its gaining volume, and RSI indicator also showing a bull trend coming nearer.
Sanofi Short Term We look to Buy at 95.00 (stop at 91.90) The medium term bias remains bullish. Levels close to the 50% pullback level of 93.25 found buyers. Previous support located at 93.08. Further upside is expected and we look to set longs in early trade. Our profit targets will be 104.35 and 110.00 Resistance: 95.16 / 98.22 / 104.35 Support: 93.25...
stock has given an ascending triangle breakout refer chart for details